Clinical Trial

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-07-12; most recent amendment 2025-03-25.
Status change: Not Yet Recruiting → Recruiting 2025-03-25
Trial Details
NCT Number NCT05460507
Lead Sponsor Plus Therapeutics
Conditions Glioma
Enrollment 40 participants
Start Date 2024-12-12
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-30